Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis and Cirrhosis, Including Those with Clinical Signs of Portal Hypertension: Interim Results from the Open-Label Assure Study with up to 4 Years of Treatment

Authors

• Aliya Gulamhusein
• Pietro Invernizzi
• Andrea Galli
• Francesca Carubbi
• Sarah Proehl
• Robert Kustra
• Jie Liu
• Kyung M. Kwon
• Daria B. Crittenden
• Palak J. Trivedi
• Stuart C. Gordon, Henry Ford HealthFollow

Recommended Citation

Gulamhusein A, Invernizzi P, Galli A, Carubbi F, Proehl S, Kustra R, Liu J, Kwon KM, Crittenden DB, Trivedi PJ, Gordon SC. Efficacy and Safety of Seladelpar in Patients with Primary Biliary Cholangitis and Cirrhosis, Including Those with Clinical Signs of Portal Hypertension: Interim Results from the Open-Label Assure Study with up to 4 Years of Treatment. J Hepatol 2026; 84:S316-S316.

Document Type

Conference Proceeding

Publication Date

5-1-2026

Publication Title

J Hepatol

Keywords

Gastroenterology & Hepatology

Volume

84

First Page

S316

Last Page

S316